InsiderTrades.com logo

Shannon Kelley Biography and Net Worth

General Counsel of Madrigal Pharmaceuticals
  • LinkedIn
  • Phone
  • Email
  • Website


Ms. Kelley has more than 20 years of diverse healthcare experience as a compliance and legal professional which will support Madrigal’s responsible growth. She joined Madrigal from Sanofi, where she served in roles of increasing responsibility. She was most recently Vice President, Chief Compliance Officer, North America and Global Specialty Care, responsible for compliance across all therapeutic areas. Prior to Sanofi, Ms. Kelley was Global Compliance and Commercial Legal Counsel for Boston Scientific Corporation. Earlier in her career, she spent ten years in enforcement roles with the U.S. Federal Government. Ms. Kelley was a Trial Attorney for the Department of Justice in Washington, D.C. and an Assistant United States Attorney and Deputy Chief of Litigation for the U.S. Attorney’s Office for the District of Massachusetts focused on healthcare matters. She is a member of the Massachusetts, D.C. and Federal bars.

What is Shannon T. Kelley's net worth?

The estimated net worth of Shannon T. Kelley is at least $5.45 million as of August 18th, 2025. Ms. Kelley owns 9,173 shares of Madrigal Pharmaceuticals stock worth more than $5,446,698 as of December 4th. This net worth evaluation does not reflect any other investments that Ms. Kelley may own. Learn More about Shannon T. Kelley's net worth.

How do I contact Shannon T. Kelley?

The corporate mailing address for Ms. Kelley and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Shannon T. Kelley's contact information.

Has Shannon T. Kelley been buying or selling shares of Madrigal Pharmaceuticals?

Shannon T. Kelley has not been actively trading shares of Madrigal Pharmaceuticals during the past quarter. Most recently, Shannon T. Kelley sold 1,304 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $367.81, for a transaction totalling $479,624.24. Following the completion of the sale, the general counsel now directly owns 9,173 shares of the company's stock, valued at $3,373,921.13. Learn More on Shannon T. Kelley's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Kenneth Bate (Director), Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Carole Huntsman (Chief Commercial Officer), Shannon Kelley (General Counsel), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 3 times. They purchased a total of 165,683 shares worth more than $61,921,142.32. During the last twelve months, insiders at the biopharmaceutical company sold shares 29 times. They sold a total of 376,125 shares worth more than $140,824,984.83. The most recent insider tranaction occured on December, 2nd when CFO Mardi Dier sold 4,173 shares worth more than $2,413,412.82. Insiders at Madrigal Pharmaceuticals own 21.5% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 12/2/2025.

Shannon T. Kelley Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2025Sell1,304$367.81$479,624.249,173View SEC Filing Icon  
1/17/2025Sell277$273.41$75,734.577,705View SEC Filing Icon  
See Full Table

Shannon T. Kelley Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Shannon T Kelley's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $586.21
Low: $573.00
High: $594.27

50 Day Range

MA: $485.24
Low: $412.35
High: $601.03

2 Week Range

Now: $586.21
Low: $265.00
High: $605.00

Volume

219,562 shs

Average Volume

339,166 shs

Market Capitalization

$13.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A